MS in 2018: new therapies and biomarkers
Posted: Sat Jan 12, 2019 2:16 pm
Multiple sclerosis in 2018: new therapies and biomarkers (2019)
https://www.thelancet.com/journals/lane ... 1/fulltext
Abstract
2018 has been a year of substantial progress in multiple sclerosis research, with breakthroughs in experimental medicine and translational research. Advances have ranged from successful clinical trials to new reports of promising biomarkers and improved understanding of the pathophysiology of multiple sclerosis.
Excerpts
More than a dozen disease-modifying therapies exist for relapsing-remitting multiple sclerosis, but only one therapy has been approved by regulators to slow progression in primary progressive multiple sclerosis (ocrelizumab), and no therapies have been approved with that specific indication in secondary progressive multiple sclerosis. Ibudilast, a phosphodiesterase inhibitor that crosses the blood–brain barrier, reduced the rate of brain atrophy by about 48% compared with placebo in the
phase 2 SPRINT-MS randomised trial1 of 255 patients with progressive multiple sclerosis, thereby leading the way to a phase 3 trial.
...
Siponimod induced a 21% reduction of the risk of 3-month confirmed disability progression compared with placebo in the
phase 3 EXPAND study2 of 1651 patients with secondary progressive multiple sclerosis.
...
In addition to the progress in treatments for progressive multiple sclerosis and paediatric multiple sclerosis in 2018, a large amount of work has focused on developing new biomarkers for neurodegeneration. Particularly notable are the studies on imaging biomarkers and serum neurofilaments.
https://www.thelancet.com/journals/lane ... 1/fulltext
Abstract
2018 has been a year of substantial progress in multiple sclerosis research, with breakthroughs in experimental medicine and translational research. Advances have ranged from successful clinical trials to new reports of promising biomarkers and improved understanding of the pathophysiology of multiple sclerosis.
Excerpts
More than a dozen disease-modifying therapies exist for relapsing-remitting multiple sclerosis, but only one therapy has been approved by regulators to slow progression in primary progressive multiple sclerosis (ocrelizumab), and no therapies have been approved with that specific indication in secondary progressive multiple sclerosis. Ibudilast, a phosphodiesterase inhibitor that crosses the blood–brain barrier, reduced the rate of brain atrophy by about 48% compared with placebo in the
phase 2 SPRINT-MS randomised trial1 of 255 patients with progressive multiple sclerosis, thereby leading the way to a phase 3 trial.
...
Siponimod induced a 21% reduction of the risk of 3-month confirmed disability progression compared with placebo in the
phase 3 EXPAND study2 of 1651 patients with secondary progressive multiple sclerosis.
...
In addition to the progress in treatments for progressive multiple sclerosis and paediatric multiple sclerosis in 2018, a large amount of work has focused on developing new biomarkers for neurodegeneration. Particularly notable are the studies on imaging biomarkers and serum neurofilaments.